Overview of Eltrombopag
Eltrombopag is an oral thrombopoietin receptor agonist, primarily indicated for the treatment of chronic immune thrombocytopenia (ITP), aplastic anemia (AA), and chronic hepatitis C-associated thrombocytopenia. It elevates platelet levels and reduces bleeding risk by stimulating the proliferation and differentiation of megakaryocytes in the bone marrow.
Mechanism of Action
Eltrombopag binds to and activates the thrombopoietin receptor (TPO-R), triggering downstream signaling pathways (e.g., the JAK-STAT pathway) to promote megakaryocyte maturation and platelet production. Its activity is independent of endogenous TPO levels, making it potentially effective in patients unresponsive to conventional therapies.
Indications and Patient Populations
Chronic Immune Thrombocytopenia (ITP)
Indicated for adult and pediatric patients (≥1 year) with an inadequate response to treatments such as corticosteroids or intravenous immunoglobulin.
Aplastic Anemia (AA)
Used in combination with immunosuppressive agents for patients with refractory AA, or as a bridging therapy prior to hematopoietic stem cell transplantation.
Chronic Hepatitis C-Associated Thrombocytopenia
Helps maintain platelet levels to enable antiviral therapy in patients with chronic hepatitis C.
Dosage and Administration
Starting Dose
The usual starting dose is 25 mg or 50 mg once daily, with dose adjustments made based on platelet counts (range: 25–75 mg daily).
Administration Timing
Eltrombopag must be taken on an empty stomach (1 hour before or 2 hours after meals), and co-administration with dairy products, calcium-containing foods, or antacids should be avoided.
Dose Adjustment and Discontinuation
Maintain the current dose when platelet counts reach ≥50×10⁹/L.
Reduce the dose or discontinue treatment if platelet counts exceed 250×10⁹/L to minimize the risk of thrombosis.
Adverse Reactions
Common Adverse Reactions
Headache (approximately 10%), nausea, diarrhea, and rash.
Serious Adverse Reactions
Hepatotoxicity: May cause elevated transaminase levels; regular monitoring of liver function is required.
Bone Marrow Fibrosis: Long-term use may increase the risk.
Thrombosis: Caution is needed when platelet counts are excessively high.
Note: The above information is not exhaustive. For complete details on dosage and adverse reactions, please refer to the full prescribing information of this product.
